Interpretable deep recommender system model for prediction of kinase inhibitor efficacy across cancer cell lines

被引:0
|
作者
Krzysztof Koras
Ewa Kizling
Dilafruz Juraeva
Eike Staub
Ewa Szczurek
机构
[1] University of Warsaw,Faculty of Mathematics, Informatics and Mechanics
[2] Merck Healthcare KGaA,Oncology Bioinformatics, Translational Medicine
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Computational models for drug sensitivity prediction have the potential to significantly improve personalized cancer medicine. Drug sensitivity assays, combined with profiling of cancer cell lines and drugs become increasingly available for training such models. Multiple methods were proposed for predicting drug sensitivity from cancer cell line features, some in a multi-task fashion. So far, no such model leveraged drug inhibition profiles. Importantly, multi-task models require a tailored approach to model interpretability. In this work, we develop DEERS, a neural network recommender system for kinase inhibitor sensitivity prediction. The model utilizes molecular features of the cancer cell lines and kinase inhibition profiles of the drugs. DEERS incorporates two autoencoders to project cell line and drug features into 10-dimensional hidden representations and a feed-forward neural network to combine them into response prediction. We propose a novel interpretability approach, which in addition to the set of modeled features considers also the genes and processes outside of this set. Our approach outperforms simpler matrix factorization models, achieving R =\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$=$$\end{document} 0.82 correlation between true and predicted response for the unseen cell lines. The interpretability analysis identifies 67 biological processes that drive the cell line sensitivity to particular compounds. Detailed case studies are shown for PHA-793887, XMD14-99 and Dabrafenib.
引用
收藏
相关论文
共 50 条
  • [31] INHIBITION OF TOPOISOMERASE I BY ERLOTINIB IN CANCER CELL LINES: EFFICACY OF COMBINED TREATMENTS WITH ERLOTINIB AND TOPOISOMERASE INHIBITOR
    Peleg, Refael
    Bobilev, Dmitri
    Priel, Esther
    ANTICANCER RESEARCH, 2008, 28 (5C) : 3452 - 3453
  • [32] THE SYNTHETIC EFFECT OF AROMATASE INHIBITOR ANASTROZOLE IN COMBINATION WITH EGFR TYROSINE KINASE INHIBITOR GEFITINIB IN NON-SMALL CELL LUNG CANCER CELL LINES
    Shen, Lan
    Lu, Shun
    Zhang, Fei Y.
    Li, Ziming
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S724 - S725
  • [33] The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines
    Shen, Lan
    Li, Ziming
    Shen, Shengping
    Niu, Xiaomin
    Yu, Yongfeng
    Li, Zonghai
    Liao, Meilin
    Chen, Zhiwei
    Lu, Shun
    LUNG CANCER, 2012, 78 (03) : 193 - 200
  • [34] The Proteasome-inhibitor Bortezomib is Active in Human Urothelial Cancer Cell Lines in Combination With the Tyrosine-kinase Inhibitor Sunitinib or Cisplatinum
    Vogl, U. M.
    Berger, W.
    Bojic, M.
    Lamm, W.
    Haitel, A.
    Kramer, G.
    Zielinski, C. C.
    Schmidinger, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S506 - S506
  • [35] Effect of palliative radiotherapy and cyclin-dependent kinase 4/6 inhibitor on breast cancer cell lines
    Sharaky, Marwa
    El Kiki, Shereen M.
    Effat, Heba
    Mansour, Heba H.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2025,
  • [36] Effect of a combination of tyrosine kinase inhibitor imatinib with doxorubicin shows hi breast cancer cell lines.
    Dahmke, L.
    Weigel, M. T.
    Bauer, M.
    Schem, C.
    Alkatout, I.
    Jonat, W.
    Mundhenke, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines
    Arlot-Bonnemains, Yannick
    Baldini, Enke
    Martin, Benedicte
    Delcros, Jean-Guy
    Toller, Matteo
    Curcio, Francesco
    Ambesi-Impiombato, Francesco S.
    D'Armiento, Massimino
    Ulisse, Salvatore
    ENDOCRINE-RELATED CANCER, 2008, 15 (02) : 559 - 568
  • [38] Cellular and molecular mechanisms of action of AS703569, a novel aurora kinase inhibitor, in human cancer cell lines
    Aissat, Nasredille
    Serova, Maria
    Ghoul, Aida
    Le Tourneau, Christophe
    Romanelli, Angela
    Gianelia-Boradorri, Athos
    Cvitovic, Esteban
    Faivre, Sandrine
    Raymond, Eric
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3591S - 3591S
  • [39] Development of a pentylenetetrazole-induced seizure model to evaluate kinase inhibitor efficacy in the central nervous system
    Morgan, L
    Neame, SJ
    Child, H
    Chung, R
    Shah, B
    Barden, L
    Staddon, JM
    Patel, TR
    NEUROSCIENCE LETTERS, 2006, 395 (02) : 143 - 148
  • [40] Basis of a FTIR spectroscopy methodology for automated evaluation of Akt kinase inhibitor on leukemic cell lines used as model
    Adrian Travo
    Vanessa Desplat
    Emmanuelle Barron
    Emilie Poychicot-Coustau
    Jean Guillon
    Gérard Déléris
    Isabelle Forfar
    Analytical and Bioanalytical Chemistry, 2012, 404 : 1733 - 1743